A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 512 participants.
Also called NCT05649137
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 512 participants
- Sponsor
- Registry
-
NCT05649137 -
2022-002235-60
-
- Other papers using this trial's data
- Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Hungary, Poland, Portugal, Slovakia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT05649137. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2024-10-28 (actual). Results posted on 2026-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
- Condition
- Obesity
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05649137- Content hash
558f78f717417c29bf42719c47e8d75fbaa681111ea9b25f5c51fe3d3fe39dd2